Browse our 650+ Publications​

Latest Publications

T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells

Lu KH, et al.
September 2022
Authors and Affiliates
Kevin Hai-Ning Lu 1,2,3, Julius Michel 1,2, Michael Kilian 1,2, Katrin Aslan1 ,2,#, Hao Qi 1,2, Niklas Kehl 1,2, Stefanie Jung 1,2, Khwab Sanghvi 1,2, Katharina Lindner 1,3,4, Xin-Wen Zhang 1,2,11, Edward W Green 1,2, Isabel Poschke 4, Miriam Ratliff 5, Theresa Bunse1 ,2, Felix Sahm 6,12, Andreas von Deimling 6,12, Wolfgang Wick 7,8, Michael Platten 1,2,4,9,10, and Lukas Bunse 1,2,*; 1 DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 3 Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen, Essen, Germany 4 Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany. 5 Department of Neurosurgery, University Hospital Mannheim, Mannheim, Germany. 6 Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany. 7 Department of Neurology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany. 8 DKTK CCU Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 9 Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany. 10 DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim Germany. 11 Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany 12 CCU Neuropathology, DKFZ, DKTK, Heidelberg, Germany. # presentaddress: Immatics Biotechnologies GmBH, Tübingen, Germany

Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression

Manjappa S, et al.
September 2022
Authors and Affiliates
Shivaprasad Manjappa 1, Huy Q Phi 2, Lik Wee Lee 3, Lynn Onstad 2, Darcy B Gill 3, Laura Connelly-Smith 1, Elizabeth F Krakow 1, Mary E Flowers 1, Paul A Carpenter 4, Joshua A Hill 5, Stephanie J Lee 6; 1 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA. 2 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. 3 Adaptive Biotechnologies, Seattle, WA. 4 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Department of Pediatrics, University of Washington, Seattle, WA. 5 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA. 6 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Department of Medicine, University of Washington, Seattle, WA. Electronic address: sjlee@fredhutch.org.

Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis

Schneider-Hohendorf T, et al.
Journal of Experimental Medicine
September 2022
Authors and Affiliates
Tilman Schneider-Hohendorf #,1, Lisa Ann Gerdes #,2,3,4, Béatrice Pignolet #,5, Rachel Gittelman 6, Patrick Ostkamp 1, Florian Rubelt 7, Catarina Raposo 8, Björn Tackenberg 8,9, Marianne Riepenhausen 1, Claudia Janoschka 1, Christian Wünsch 1, Florence Bucciarelli 5, Andrea Flierl-Hecht 2,3,4, Eduardo Beltrán 2,3,4, Tania Kümpfel 2,3,4, Katja Anslinger 10, Catharina C Gross 1, Heidi Chapman 6, Ian Kaplan 6, David Brassat 8, Hartmut Wekerle 2,11, Martin Kerschensteiner 2,3,4, Luisa Klotz 1, Jan D Lünemann 1, Reinhard Hohlfeld 2,3, Roland Liblau #,5, Heinz Wiendl #,1, Nicholas Schwab #,1; 1 Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. 2 Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians Universität München, Munich, Germany. 3 Biomedical Center, Faculty of Medicine, Ludwig-Maximilians Universität München, Martinsried, Germany. 4 Munich Cluster of Systems Neurology (SyNergy), Munich, Germany. 5 Toulouse Institute for infectious and inflammatory diseases (Infinity), University of Toulouse, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université Paul Sabatier, Toulouse, France. 6 Adaptive Biotechnologies, Seattle, WA. 7 Roche Sequencing Solutions, Pleasanton, CA. 8 F. Hoffmann-La Roche Ltd, Basel, Switzerland. 9 Philipps-University, Department of Neurology, Marburg, Germany. 10 Institute of Legal Medicine, Ludwig-Maximilians Universität München, Munich, Germany. 11 Institute for Biological Intelligence, Martinsried, Germany. # Contributed equally.

Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19

Chung A, et al.
British Journal of Haematology
September 2022
Authors and Affiliates
Alfred Chung 1, Barbara Banbury 2, Marissa Vignali 2, Chiung-Yu Huang 3, Sireesha Asoori 1, Rachel Johnson 4, Theodore Kurtz 5, Shagun Arora 1, Sandy W Wong 1, Nina Shah 1, Thomas G Martin 1, Jeffrey L Wolf 1; 1 Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA. 2 Adaptive Biotechnologies Corp, Seattle, Washington, USA. 3 Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA. 4 American University of the Caribbean School of Medicine, St. Maarten. 5 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.

Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

Berner F, et al.
Science Immunology
September 2022
Authors and Affiliates
Fiamma Berner 1, David Bomze 1,2,3, Christa Lichtensteiger 1, Vincent Walter 4, Rebekka Niederer 1,5, Omar Hasan Ali 1,6,7, Nina Wyss 1,5, Jens Bauer 8,9,10, Lena Katharina Freudenmann 9,11, Ana Marcu 9, Eva-Maria Wolfschmitt 9, Sebastian Haen 9, Thorben Gross 9, Marie-Therese Abdou 1, Stefan Diem 12, Stella Knöpfli 1, Tobias Sinnberg 4,10, Kathrin Hofmeister 4, Hung-Wei Cheng 1, Marieta Toma 13, Niklas Klümper 14,15, Mette-Triin Purde 1, Oltin Tiberiu Pop 1, Ann-Kristin Jochum 1,16, Steve Pascolo 7, Markus Joerger 12, Martin Früh 12,17, Wolfram Jochum 16, Hans-Georg Rammensee 9,10,11, Heinz Läubli 18, Michael Hölzel 15, Jacques Neefjes 19, Juliane Walz 8,9,10,11,20, Lukas Flatz 1,4,5,7,12; 1 Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 4 Department of Dermatology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany. 5 Department of Dermatology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 6 Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada. 7 Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 8 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany. 9 Interfaculty Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 10 Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany. 11 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany. 12 Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 13 Institute of Pathology, University Hospital Bonn (UKB), University of Bonn, Bonn, Germany. 14 Department of Urology, University Hospital Bonn (UKB), University of Bonn, Bonn, Germany. 15 Institute of Experimental Oncology, University Hospital Bonn (UKB), University of Bonn, Bonn, Germany. 16 Institute of Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 17 Department of Oncology, University of Bern, Bern, Switzerland. 18 Division of Oncology, University Hospital Basel, University of Basel, Basel, Switzerland. 19 Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Netherlands. 20 Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany.

Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients

Muraro E, et al.
Frontiers in Oncology
September 2022
Authors and Affiliates
Elena Muraro 1, Fabio Del Ben 2, Matteo Turetta 1, Daniela Cesselli 2,3, Michela Bulfoni 3, Rita Zamarchi 4, Elisabetta Rossi 4,5, Simon Spazzapan 6, Riccardo Dolcetti 7,8,9,10, Agostino Steffan 1, Giulia Brisotto 1; 1 Immunopathology and Cancer Biomarkers Units, Department of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy. 2 Department of Medicine, University of Udine, Udine, Italy. 3 Institute of Pathology, University Hospital of Udine (Azienda sanitaria universitaria Friuli Centrale, ASUFC), Udine, Italy. 4 Department of Surgery, Oncology & Gastroenterology, University of Padova, Padua, Italy. 5 Veneto Institute of Oncology IOV - Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy. 6 Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy. 7 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 8 Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. 9 Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia. 10 The University of Queensland Diamantina Institute, Brisbane, QLD, Australia.

SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children

Lam KP, et al.
Clinical Immunology
September 2022
Authors and Affiliates
Ki Pui Lam 1, Marcos Chiñas 2, Amélie M Julé 3, Maria Taylor 1, Marina Ohashi 4, Mehdi Benamar 1, Elena Crestani 1, Mary Beth F Son 1, Janet Chou 1, Catherine Gebhart 4, Talal Chatila 1, Jane Newburger 5, Adrienne Randolph 6, Maria Gutierrez-Arcelus 2, Lauren A Henderson 7; 1 Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. 2 Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. 3 Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. 4 HLA-Lab, American Red Cross, Dedham, MA, USA. 5 Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. 6 Division of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. 7 Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: lauren.henderson@childrens.harvard.edu.

T Cell Receptor Sequencing Reveals Reduced Clonal Breadth of T Cell Responses against SARS-CoV-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Pradier A, et al.
Annals of Oncology
September 2022
Authors and Affiliates
A Pradier 1, A C Mamez 2, C Stephan 3, F Giannotti 3, S Masouridi-Levrat 3, S Wang 4, S Morin 3, D Neofytos 5, D L Vu 5, A Melotti 4, I Arm 6, C S Eberhardt 7, J Tamburini 4, L Kaiser 8, Y Chalandon 1, F Simonetta 9; 1 Division of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland; Translational Research Centre in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 2 Division of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland. Electronic address: anne-claire.mamez@hcuge.ch. 3 Division of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland. 4 Translational Research Centre in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 5 Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland. 6 Laboratory of Virology, Division of Infectious Diseases and Division of Laboratory Medicine, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland. 7 Center for Vaccinology, University Hospitals of Geneva Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 8 Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; Laboratory of Virology, Division of Infectious Diseases and Division of Laboratory Medicine, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland; Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland. 9 Division of Hematology, Department of Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland; Translational Research Centre in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: federico.simonetta@unige.ch.

Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model

Kang J, et al.
Journal for ImmunoTherapy of Cancer
September 2022
Authors and Affiliates
Jinho Kang ,1 Hye-Jin Lee,1 Jimin Lee,1 Jinhwa Hong,1 Yeul Hong Kim,1 Mary L Disis,2 Jeong-An Gim,3 Kyong Hwa Park1; 1 Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea. 2 Department of Medicine, University of Washington, Seattle, Washington, USA. 3 Center for Research Support, Korea University College of Medicine, Seoul, South Korea. 4 Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea khpark@korea.ac.kr.

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.

Slade M, et al.
September 2022
Authors and Affiliates
Michael Slade 1, Thomas G. Martin2, Nitya Nathwani3, Mark A. Fiala 1, Michael P. Rettig1, Feng Gao1, Abhinav Deol4,Francis K. Buadi 5, Jonathan L. Kaufman 6, Craig C. Hofmeister 6, Tara K. Gregory7, Jesus Berdeja 8, Ajai Chari9,Ashley Rosko10 and Ravi Vij1 1Washington University School of Medicine, St. Louis, MO, USA. 2University of California- San Francisco, San Francisco, CA, USA. 3Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 4Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 5Mayo Clinic, Rochester,MN, USA. 6Emory University, Atlanta, GA, USA. 7Sarah Cannon Research Institute, Denver, CO, USA. 8Sarah Cannon Research Institute, Nashville, TN, USA. 9Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 10Ohio State University, Columbus, OH, USA.
Previous Next